Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AMTINASDAQ:BDRXNASDAQ:LEXX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMTIApplied Molecular Transport$0.26$0.24$0.13▼$0.84$10.87M2.28470,969 shsN/ABDRXBiodexa Pharmaceuticals$1.05-8.7%$1.43$1.04▼$41.50$38.37M1.15841,312 shs518,232 shsLEXXLexaria Bioscience$1.02-2.9%$1.33$0.95▼$4.44$17.91M0.9156,982 shs34,896 shs20 Stocks to Sell NowToday, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMTIApplied Molecular Transport0.00%0.00%0.00%0.00%0.00%BDRXBiodexa Pharmaceuticals0.00%-12.88%-25.81%-66.95%+114,999,900.00%LEXXLexaria Bioscience-4.55%+7.14%-22.22%-30.33%-66.35%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAMTIApplied Molecular TransportN/AN/AN/AN/AN/AN/AN/AN/ABDRXBiodexa Pharmaceuticals0.9079 of 5 stars0.05.00.00.02.40.00.6LEXXLexaria Bioscience2.3724 of 5 stars3.52.00.00.03.31.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAMTIApplied Molecular Transport 0.00N/AN/AN/ABDRXBiodexa Pharmaceuticals 0.00N/AN/AN/ALEXXLexaria Bioscience 3.00Buy$7.00586.27% UpsideCurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAMTIApplied Molecular TransportN/AN/AN/AN/A$1.56 per shareN/ABDRXBiodexa Pharmaceuticals$83K462.30N/AN/A$42.56 per share0.02LEXXLexaria Bioscience$525.92K34.05N/AN/A$0.48 per share2.13Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAMTIApplied Molecular Transport-$126.32M-$1.90N/AN/AN/AN/A-223.46%-126.91%N/ABDRXBiodexa Pharmaceuticals-$7.66MN/A0.00N/AN/AN/AN/AN/AN/ALEXXLexaria Bioscience-$5.80M-$0.59N/AN/AN/A-1,473.04%-88.88%-83.59%7/11/2025 (Estimated)Latest AMTI, BDRX, and LEXX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails4/14/2025Q2 2025LEXXLexaria Bioscience-$0.16-$0.15+$0.01-$0.15$0.14 million$0.17 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAMTIApplied Molecular TransportN/AN/AN/AN/AN/ABDRXBiodexa PharmaceuticalsN/AN/AN/AN/AN/ALEXXLexaria BioscienceN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAMTIApplied Molecular TransportN/A4.994.99BDRXBiodexa Pharmaceuticals0.022.16N/ALEXXLexaria BioscienceN/A29.6229.62Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAMTIApplied Molecular Transport41.79%BDRXBiodexa Pharmaceuticals17.51%LEXXLexaria Bioscience13.06%Insider OwnershipCompanyInsider OwnershipAMTIApplied Molecular Transport15.90%BDRXBiodexa Pharmaceuticals0.34%LEXXLexaria Bioscience26.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAMTIApplied Molecular Transport1341.34 million34.76 millionOptionableBDRXBiodexa Pharmaceuticals2036.54 million36.42 millionNot OptionableLEXXLexaria Bioscience717.56 million12.92 millionNot OptionableAMTI, BDRX, and LEXX HeadlinesRecent News About These CompaniesLexaria Provides Update on Material Transfer Agreement with Pharmaceutical CompanyMay 12, 2025 | accessnewswire.comLexaria Provides Update on Material Transfer Agreement with Pharmaceutical CompanyMay 12, 2025 | thenewswire.comLexaria Announces Closing of $2 Million Registered Direct Offering of Common StockApril 28, 2025 | thenewswire.comLexaria Announces Closing of $2 Million Registered Direct Offering of Common StockApril 28, 2025 | accessnewswire.comLexaria Bioscience prices 2M shares at $1.00 in registered direct offeringApril 26, 2025 | markets.businessinsider.comLexaria Announces $2 Million Registered Direct Offering of Common StockApril 25, 2025 | accessnewswire.comLexaria Announces $2 Million Registered Direct Offering of Common StockApril 25, 2025 | thenewswire.comLexaria provides GLP-1 update following industry developmentsApril 23, 2025 | markets.businessinsider.comRecent GLP-1-Industry Developments Highlight the Promise of Lexaria Bioscience’s TechnologyApril 23, 2025 | finance.yahoo.comRecent GLP-1-Industry Developments Highlight the Promise of Lexaria Bioscience's TechnologyApril 23, 2025 | accessnewswire.comWe Think Lexaria Bioscience (NASDAQ:LEXX) Needs To Drive Business Growth CarefullyApril 5, 2025 | uk.finance.yahoo.comLexaria Updates its Ongoing Human Study GLP-1-H24-4April 3, 2025 | accessnewswire.comLexaria Updates its Ongoing Human Study GLP-1-H24-4April 3, 2025 | thenewswire.comLexaria Bioscience begins dosing for GLP-1 study #5April 3, 2025 | markets.businessinsider.comLexaria's Human GLP-1 Study #5 Begins DosingApril 2, 2025 | accessnewswire.comLexaria's DehydraTECH-tirzepatide Oral Capsules Achieve Comparable Levels in Bloodstream as Eli Lilly's Injectable Zepbound(R)March 18, 2025 | accessnewswire.comLexarias' DehydraTECH-tirzepatide Oral Capsules Achieve Comparable Levels in Bloodstream as Eli Lilly's Injectable ZepboundMarch 18, 2025 | thenewswire.comLexaria Bioscience Corp.: The Global Revolution in Healthcare Driven by GLP-1 Drugs and the role of Lexaria BioscienceFebruary 27, 2025 | finanznachrichten.deThe Global Revolution in Healthcare Driven by GLP-1 Drugs and the role of Lexaria BioscienceFebruary 27, 2025 | accessnewswire.comThe Global Revolution in Healthcare Driven by GLP-1 Drugs and the role of Lexaria BioscienceFebruary 27, 2025 | thenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAMTI, BDRX, and LEXX Company DescriptionsApplied Molecular Transport NASDAQ:AMTIApplied Molecular Transport Inc., a clinical-stage biopharmaceutical company, engages in the design and development of a pipeline of oral biologic product candidates to treat autoimmune, inflammatory, metabolic, and other diseases. The company's lead product candidate is AMT-101, a gastrointestinal (GI) selective oral fusion of rhIL-10 that is in Phase II clinical trials to treat patients with chronic pouchitis, as well as is in Phase II development to treat patients with rheumatoid arthritis. It develops AMT-126, a GI-selective oral fusion of interleukin 22, which is in a Phase I clinical trial for diseases related to intestinal epithelium barrier function defects. The company, through its technology platform, designs and develops various oral and respiratory biologic therapeutic modalities, such as peptides, proteins, antibodies, antibody fragments, and ribonucleic acid therapeutics. Applied Molecular Transport Inc. was founded in 2010 and is headquartered in South San Francisco, California. As of December 27, 2023, Applied Molecular Transport Inc. operates as a subsidiary of Cyclo Therapeutics, Inc.Biodexa Pharmaceuticals NASDAQ:BDRX$1.05 -0.10 (-8.70%) Closing price 04:00 PM EasternExtended Trading$1.04 -0.01 (-1.05%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma; and MTD217, a program centered around a water-soluble drug formulation that can be easily infused or injected simultaneously, or sequentially, directly into the cancer microenvironment, currently under preclinical studies for the treatment of leptomeningeal disease. In addition, the company offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. It has collaboration agreements with Janssen and Melior. The company was formerly known as Midatech Pharma plc and changed its name to Biodexa Pharmaceuticals Plc in March 2023. Biodexa Pharmaceuticals Plc was founded in 2000 and is headquartered in Cardiff, the United Kingdom.Lexaria Bioscience NASDAQ:LEXX$1.02 -0.03 (-2.86%) Closing price 04:00 PM EasternExtended Trading$1.02 +0.00 (+0.20%) As of 07:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Lexaria Bioscience Corp. operates as a biotechnology company. It develops and out-licenses its patented drug delivery technology, DehydraTECH, which combines lipophilic molecules or active pharmaceutical ingredients with specific long-chain fatty acids and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing while promoting healthier oral ingestion methods. The company's DehydraTECH is used with a range of active molecules encompassing fat-soluble vitamins, pain medications, hormones, PDE5 inhibitors, antivirals, oral nicotine and its analogs, and cannabinoids. Its DehydraTECH technology evaluates therapeutic indications, including hypertension, heart disease, and diabetes; and is suitable for a variety of product formats, such as pharmaceuticals, nutraceuticals, over the counter, and consumer packaged goods. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Toyota Supercharges Joby: $250M Capital Infusion Ignites Stock GameStop Buys Bitcoin: Smart Strategy or Big Mistake? Qualcomm Stock Turns South: 3 Entry Signals to Watch For D-Wave Quantum Stock: Are Advantage2 Gains Here to Stay? Meta's Institutional & Insider Data Fuels Bulls Despite Disparity Is Michael Burry Right Betting Against the Market Again? Amer Sports: The New ONON and DECK of Consumer Discretionary? BigBear.ai: Risky AI Stock or Defense Tech Opportunity? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
